SEC Form 4 · accession 0000899243-16-033097
CORCEPT THERAPEUTICS INC · CORT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph K Belanoff
Officer — CHIEF EXECUTIVE OFFICER · Director
Period of report
Nov 7, 2016
Accepted (ET)
Nov 9, 2016 · 8:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001088856
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 7, 2016 | M | 93,533 | $1.50 | A | 2,257,728 | D | |
| Common StockF1 | Nov 7, 2016 | S | 93,533 | $8.2212 | D | 2,164,195 | D | |
| Common Stock | Nov 7, 2016 | M | 406,467 | $1.50 | A | 2,570,662 | D | |
| Common StockF2 | Nov 7, 2016 | S | 406,467 | $8.3244 | D | 2,164,195 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $1.50 | Nov 7, 2016 | M | 93,533 | D | — | Apr 16, 2017 | Common Stock | 93,533 | 906,467 | D |
| Stock Option (Right to Buy)F3 | $1.50 | Nov 7, 2016 | M | 406,467 | D | — | Apr 16, 2017 | Common Stock | 406,467 | 500,000 | D |
Explanation of responses
- F1Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $8.22 to $8.24 per share. Detailed information on the exact number of shares sold at each sale price can be obtained upon request.
- F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $8.27 to $8.375 per share. Detailed information on the exact number of shares sold at each sale price can be obtained upon request.
- F3Fully exercisable.